Clinical comparison of Healon5 (sodium hyaluronate 2.3%) and Healon (sodium hyaluronate 1.0%) in phacoemulsification

Clinical comparison of Healon5 and Healon in phacoemulsification and intraocular lens implantation: A Randomized, Prospective, Multicenter Clinical study.

Article specifications

This article was published in 2004, in journal of cataract & refractive surgery (IF 2015:2.72) by Japanese ophthalmologists. In this study the effect on intraocular pressure (IOP), and the effect on corneal endothelium of Healon5® (sodium hyaluronate 2.3%) and Healon® (sodium hyaluronate 1.0%) were compared during phacoemulsification and intraocular lens (IOL) implantation. This study comprised 157 patients were performance phacoemulsification and IOL implantation in 7 surgical centers. Patients divided in 2 groups: Healon 5 group comprised 79 patients and Healon group with 78 patients.  The IOP was measured using a Goldmann applanation tonometer preoperatively and 5 and 24 hours, 7 days, and 3 months postoperatively. Specular microscopy was performed preoperatively and 3 months after surgery. Corneal thickness was measured by ultrasound pachymetry preoperatively and 24 hours, 7 days, and 3 months after surgery. Pachymetry measurements were repeated at least 3 times, and their mean was used for analysis.

Results

The results of the study showed that Healon5(sodium hyaluronate 2.3%) is useful in creating and maintaining a deep anterior chamber for safe phacoemulsification and IOL implantation. It has greater retention in the eye during phacoemulsification and superior anterior chamber maintenance at the time of CCC and IOL implantation.